Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Medical Device

Nanjing Novlead Bio Files Hong Kong IPO – Nitric Oxide Therapy Specialist Targets Critical Care Market

Fineline Cube Mar 3, 2026
Company Deals

Boehringer Ingelheim Licenses Sitryx Autoimmune Program – $500M+ Deal for Oral Disease‑Modifying Therapy

Fineline Cube Mar 3, 2026
Company Deals

ArkBio Partners with Qilu Pharma on Azstarys China Commercialization – ADHD Therapy Market Entry

Fineline Cube Mar 3, 2026
Company Deals

QL Biopharma Raises 500M+ RMB Series C – OrbiMed Leads Round for Monthly GLP‑1 Zovigrutide

Fineline Cube Mar 2, 2026
Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Policy / Regulatory

NMPA CDE Launches “Caring Program – Extension” Pilot – Accelerates Rare Disease Drug Development Pathway

Fineline Cube Mar 2, 2026
Company Drug

Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II

Fineline Cube Mar 3, 2026
Company Drug

Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes

Fineline Cube Mar 3, 2026
Company Drug

Beijing Wantai Initiates Phase I Study for 20-Valent Pneumonia Vaccine

Fineline Cube Feb 14, 2023

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has announced the initiation and...

Company Drug

Gracell Biotechnologies Gains IND Approval for GC012F in China

Fineline Cube Feb 14, 2023

Gracell Biotechnologies has reported receiving Investigational New Drug (IND) approval from the Center for Drug...

Hospital Policy / Regulatory

China’s Ministries Release Plan for Urban Medical Group Pilots

Fineline Cube Feb 14, 2023

A group of ministries led by the National Health Commission (NHC), including the National Development...

Company Deals Digital

ThinmedTech Partners with West China Hospital for CKD Digital Therapy

Fineline Cube Feb 14, 2023

ThinmedTech, a chronic disease clinical management solution provider based in Chongqing, has struck a partnership...

Company Drug

RemeGen Gains NMPA Approval for RC48 and Pyrotinib Clinical Study

Fineline Cube Feb 14, 2023

China-based RemeGen Ltd (HKG: 9995) has announced receiving the go-ahead from the National Medical Products...

Company Drug

Clover Biopharmaceuticals Administers First Dose of COVID-19 Vaccine SCB-2019 in Zhejiang

Fineline Cube Feb 14, 2023

China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced the first jab of its COVID-19 vaccine...

Company Deals

Hengrui Pharmaceuticals Licenses SHR2554 to Treeline Biosciences

Fineline Cube Feb 13, 2023

China’s Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced a licensing agreement with US-based Treeline Biosciences,...

Company Deals Drug

CSPC Pharmaceutical Licenses ADC SYS6002 to Corbus Pharmaceuticals

Fineline Cube Feb 13, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced a licensing agreement with Massachusetts-based Corbus...

Company Deals

Mingche Biotechnology Secures Pre-Series A Funding for Medical Device Innovation

Fineline Cube Feb 13, 2023

China-based high-value medical device firm Mingche Biotechnology (Suzhou) Co., Ltd has reportedly raised “tens of...

Company Deals

Dessight Biomedical Secures Pre-Series A Funding for Ophthalmic Innovations

Fineline Cube Feb 13, 2023

Hangzhou Dessight Biomedical has reportedly raised “tens of millions” of renminbi in a Pre-Series A...

Company Drug

Luye Pharma Initiates Phase I Study for BA1106, a CD25 Monoclonal Antibody

Fineline Cube Feb 13, 2023

China-based Luye Pharma Group (HKG: 2186) has announced the first subject dosing in a Phase...

Company Drug

Zelgen’s ZGGS15 Accepted for NMPA Review as First Global BsAb Filing

Fineline Cube Feb 13, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that a clinical trial filing for...

Company Drug

Kintor’s GT20029 Shows Positive Results in US Phase I Study for AGA and Acne

Fineline Cube Feb 13, 2023

China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced positive topline data from a Phase I...

Company Drug

Hengrui’s HER2-Targeted ADC SHR-A1811 Aims for Breakthrough Designation

Fineline Cube Feb 13, 2023

China’s Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced that its SHR-A1811, an HER2 targeted antibody-drug...

Company Drug

EOC Pharma’s CDK7 Inhibitor EOC237 Accepted for CDE Review

Fineline Cube Feb 13, 2023

EOC Pharma, a biotech operating out of the US and China, has announced that a...

Company Drug

Joincare’s Generic Seretide Accepted for NMPA Review

Fineline Cube Feb 10, 2023

China-based Joincare Pharmaceutical Industry Group Co., Ltd (SHA: 600380) has announced that the market filing...

Company Deals

Nona Biosciences Partners with Mythic Therapeutics for Next-Gen ADCs

Fineline Cube Feb 10, 2023

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has struck a partnership...

Company Drug

Everest Medicines’ Nefecon Included in South Korea’s GIFT Program

Fineline Cube Feb 10, 2023

China-based Everest Medicines (HKG: 1952) has announced that South Korea’s Ministry of Food and Drug...

Company Deals

Haohai Bio Acquires Additional Stake in SZNIMO for Ophthalmic Expansion

Fineline Cube Feb 10, 2023

China-based Shanghai Haohai Biological Technology Co. Ltd (HKG: 6826, SHA: 688366), a leading biomaterial firm...

Company Drug

Hinova’s HP530S Accepted for NMPA Review as FAK Inhibitor for Solid Tumors

Fineline Cube Feb 10, 2023

China-based biopharma Hinova Pharmaceuticals (SHA: 688302) has announced that a clinical trial filing for its...

Posts pagination

1 … 527 528 529 … 629

Recent updates

  • MicroPort Endovascular’s Hector Wins FDA Breakthrough Designation – Multi‑Branch Stent Graft Targets Complex Aortic Arch Lesions
  • Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II
  • Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes
  • Lepu Medical’s siRNA MWX401 Wins NMPA Approval – RNAi Therapy Targets Primary Hypertension
  • Xellsmart’s iPSC Neural Therapy Cleared by NMPA and FDA – First “Off‑the‑Shelf” Cell Therapy for MSA‑P Enters Clinic
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Medical Device

MicroPort Endovascular’s Hector Wins FDA Breakthrough Designation – Multi‑Branch Stent Graft Targets Complex Aortic Arch Lesions

Company Drug

Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II

Company Drug

Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes

Company Drug

Lepu Medical’s siRNA MWX401 Wins NMPA Approval – RNAi Therapy Targets Primary Hypertension

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.